Physician profile
Susmitha Apuri
NPI 1154598068
$14,135.82
in general payments reported to CMS, 2019-2025
70 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,553 · 2020: $1,774 · 2021: $1,215 · 2022: $1,501 · 2023: $1,820 · 2024: $2,783 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,092.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,151.76 | 2019-2025 | Kisqali, Piqray |
| E.R. Squibb & Sons, L.L.C. | $1,003.87 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $917.78 | 2019-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $907.00 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $638.55 | 2019-2025 | |
| Janssen Biotech, INC. | $634.18 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Astrazeneca Pharmaceuticals LP | $585.35 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Incyte Corporation | $544.84 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Pfizer INC. | $510.97 | 2019-2025 | |
| Gilead Sciences, INC. | $499.37 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $482.84 | 2019-2025 | |
| Lilly USA, LLC | $460.37 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $377.01 | 2019-2025 | |
| Seagen INC. | $364.01 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $330.97 | 2019-2025 | Phesgo, Kadcyla, Venclexta |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $329.87 | 2019-2025 | |
| Amgen INC. | $329.19 | 2019-2023 | Xgeva, Nplate, Lumakras |
| Octapharma USA, INC. | $271.63 | 2020-2021 | |
| Foundation Medicine, INC. | $266.98 | 2019-2021 | |
| Daiichi Sankyo INC. | $263.97 | 2019-2025 | Enhertu, Datroway |
| Emd Serono, INC. | $261.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $246.05 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $229.14 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Abbvie INC. | $168.99 | 2022-2025 | Venclexta |
| Jazz Pharmaceuticals INC. | $136.05 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.11 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $118.48 | 2020-2025 | Xpovio |
| Beigene USA, INC. | $113.84 | 2021-2025 | Brukinsa |
| Mirati Therapeutics, INC. | $107.06 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $102.74 | 2019-2025 | Tavalisse, Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $93.27 | 2022-2023 | Yescarta |
| Taiho Oncology, INC. | $92.36 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $92.35 | 2019-2023 | Pyrukynd |
| Array Biopharma INC | $89.29 | 2019-2025 | Mektovi, Lorbrena, Braftovi |
| Sobi, INC | $86.24 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $86.02 | 2019-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $71.95 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $69.86 | 2019-2025 | Iclusig, Vpriv |
| Pharmacyclics LLC, An Abbvie Company | $68.77 | 2019-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $68.17 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $66.80 | 2022-2024 | Fotivda |
| Adc Therapeutics America, INC. | $59.44 | 2024-2025 | |
| Beone Medicines USA, INC. | $52.25 | 2025 | Brukinsa, Tevimbra |
| Amag Pharmaceuticals, INC. | $46.73 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $39.19 | 2024-2025 | Provenge |
| Tempus Ai, INC | $36.40 | 2024 | Xt Cdx |
| G1 Therapeutics, INC. | $36.13 | 2023 | Cosela |
| Clovis Oncology, INC. | $34.90 | 2019 | |
| Exelixis INC. | $33.14 | 2019-2023 | Cabometyx |
| Lexicon Pharmaceuticals, INC. | $29.64 | 2019-2020 | |
| Blueprint Medicines Corporation | $26.86 | 2023 | Ayvakit |
| Heron Therapeutics, INC. | $25.38 | 2020-2021 | |
| Aurobindo Pharma USA, INC. | $24.91 | 2019 | |
| Tersera Therapeutics LLC | $24.06 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.66 | 2020 | |
| Fennec Pharmaceuticals, INC. | $23.47 | 2024 | Pedmark |
| Secura Bio, INC. | $23.39 | 2020 | |
| Legend Biotech USA INC. | $23.27 | 2024 | |
| Tesaro, INC. | $22.25 | 2019 | |
| Myriad Genetic Laboratories, INC. | $22.23 | 2023 | Precisetumor |
| Csl Behring | $20.59 | 2021 | |
| Epizyme, INC. | $20.10 | 2022 | |
| Mylan Institutional INC. | $19.60 | 2019 | |
| Stemline Therapeutics INC. | $19.10 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $18.27 | 2024 | Cosela |
| Teleflex LLC | $16.67 | 2025 | Arrow |
| Partner Therapeutics, INC. | $16.45 | 2019 | |
| Verastem, INC. | $16.06 | 2019 | |
| Acrotech Biopharma INC. | $14.46 | 2024 | Beleodaq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susmitha Apuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.